BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36422807)

  • 21. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.
    Ye X; Chen D; Zheng Y; Wu C; Zhu X; Huang J
    Hematol Oncol; 2019 Oct; 37(4):438-446. PubMed ID: 31378958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
    Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota V
    Leuk Res; 2018 Aug; 71():27-33. PubMed ID: 29944984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
    Leleu X; Soumerai J; Roccaro A; Hatjiharissi E; Hunter ZR; Manning R; Ciccarelli BT; Sacco A; Ioakimidis L; Adamia S; Moreau AS; Patterson CJ; Ghobrial IM; Treon SP
    J Clin Oncol; 2009 Jan; 27(2):250-5. PubMed ID: 19064987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
    Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
    J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical Study of Patients with Myelodysplastic Syndrome Transformed into Acute Myeloid Leukemia].
    Ye F; Ma DS; Wang J; Qiao ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):202-207. PubMed ID: 29397844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Ertz-Archambault N; Kosiorek H; Taylor GE; Kelemen K; Dueck A; Castro J; Marino R; Gauthier S; Finn L; Sproat LZ; Palmer J; Mesa RA; Al-Kali A; Foran J; Tibes R
    JAMA Oncol; 2017 Jul; 3(7):936-943. PubMed ID: 28152123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.
    Bell JA; Galaznik A; Blazer M; Shih HC; Farrelly E; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV
    Pharmacoecon Open; 2019 Jun; 3(2):237-245. PubMed ID: 30324565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 34. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
    Kaplan HG; Malmgren JA; Atwood MK
    BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
    Kaplan H; Malmgren J; De Roos AJ
    Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of acute myeloid leukemia and high-risk myelodysplastic syndrome according to health insurance status.
    Al-Ameri A; Anand A; Abdelfatah M; Kanaan Z; Hammonds T; Haller N; Cherry M
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):509-13. PubMed ID: 25108681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
    Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare resource utilization and economic burden of antifungal management in patients with hematologic malignancy in Japan: a retrospective database study.
    Ueno R; Nishimura S; Fujimoto G; Ainiwaer D
    Curr Med Res Opin; 2021 Jul; 37(7):1121-1134. PubMed ID: 33989102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome.
    Gao L; Saeed A; Golem S; Zhang D; Woodroof J; McGuirk J; Ganguly S; Abhyankar S; Lin TL; Cui W
    Int J Lab Hematol; 2021 Feb; 43(1):99-109. PubMed ID: 32812335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals.
    Rieger CT; Cornely OA; Hoppe-Tichy T; Kiehl M; Knoth H; Thalheimer M; Schuler U; Ullmann AJ; Ehlken B; Ostermann H
    Mycoses; 2012 Nov; 55(6):514-20. PubMed ID: 22471310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.